{"id":130130,"date":"2026-08-05T10:55:07","date_gmt":"2026-08-05T10:55:07","guid":{"rendered":"https:\/\/www.europesays.com\/ai\/130130\/"},"modified":"2026-08-05T10:55:07","modified_gmt":"2026-08-05T10:55:07","slug":"recursion-partners-with-genentech-to-advance-first-validated-neuro-target-discovered-through-ai-map","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ai\/130130\/","title":{"rendered":"Recursion Partners with Genentech to Advance First Validated Neuro Target Discovered Through AI Map"},"content":{"rendered":"

\"\"<\/a>Christopher Winrow, PhD, Recursion\u2019s vice president of neuroscience, inside the company\u2019s lab. Recursion marked a milestone in its up to $12 billion artificial intelligence (AI) collaboration with Roche, and its Genentech subsidiary Wednesday when plans were announced for Recursion and Genentech to co-develop a neuroscience discovery program based on the first validated target discovered through an AI map they created to find new targets in a long-challenging therapeutic area. [Recursion]<\/p>\n

The 4.5 year, up-to-$12 billion artificial intelligence (AI) drug discovery collaboration of Recursion, Roche, and its Genentech subsidiary marked a milestone Wednesday when plans were announced for Recursion and Genentech to co-develop a neuroscience small molecule early discovery program based on the first validated target discovered through an AI map they created to find new targets in a long-challenging therapeutic area.<\/p>\n

Genentech has exercised the collaboration\u2019s first validated target option after accepting from Recursion a validation package for the target. That acceptance will trigger a $3 million milestone payment from the biopharma giants to Recursion. That latest payment raises to $216 million the total cash paid out by the biopharma giants to Recursion since the AI-based drug developer joined with the pharma giant and its subsidiary to launch their partnership in 2021.<\/p>\n

For each program developed, Recursion can receive up to $300 million in payments tied to achieving development, commercialization, and net sales milestones, as well as tiered royalties up to high single digits per small molecule program. Roche and Genentech have committed to using Recursion\u2019s platform to advance therapies in 40 programs that include \u201ckey areas\u201d of neuroscience and an undisclosed gastrointestinal (GI)-oncology indication.<\/p>\n

The companies are not disclosing what the target is, or what neuroscience disorders it has the potential to treat. Recursion does say, however, that it took the companies 15 months to go from initiation of target validation to a validation package.<\/p>\n

The target\u2019s significance, according to Recursion and its partners, rests in its potential to expand the universe of neuroscience treatments beyond the handful of familiar targets in the space.<\/p>\n

While more than three billion people are affected by neurological conditions worldwide, only one in 40 neuroscience drugs to ever reach the clinic have been approved. Just 8.4% of neurology drug candidates that enter Phase I studies reach all the way to approval, according to a Clinical Development Success Rates 2006-2015, a study published by the Biotechnology Innovation Organization (BIO), BioMedTracker, and Amplion (acquired in 2022 by Science and Medicine Group or SMG).<\/p>\n

\u201cFinding new targets in neuroscience has historically been challenging, and this milestone highlights our ability to uncover novel biology in areas where conventional approaches have struggled,\u201d Recursion CEO Najat Khan, PhD, said in a statement.<\/p>\n

New tools<\/p>\n

New hope for discovering and developing new neuroscience drugs, the companies say, is a result of new tools developed to study the mostly unexplored genome in living neurons.<\/p>\n

Those new tools start with Recursion\u2019s Data Factory, an end-to-end platform developed and perfected for more than a decade to create a repeatable, scalable system for generating biological data designed for AI models.<\/p>\n

\u201cWe really took an approach to be unbiased in our full genome-wide scan of these opportunities to uncover new biology,\u201d Christopher Winrow, PhD, Recursion\u2019s vice president of neuroscience, told GEN.<\/p>\n

Partnering with Roche and Genentech, Recursion built the first whole-genome CRISPR knockout map generated from a subset of over one trillion internally manufactured neuronal cells derived from induced pluripotent stem cells (iPSCs)\u2014about 12 brains\u2019 worth of neurons\u2014after outside cell manufacturers told the partners that the scale of production they were seeking was too difficult and too expensive to carry out.<\/p>\n

\u201cThe cell context is important. We\u2019re starting with human iPSCs and driving these into a very clearly homogenous population of neurons that we can test\u2014and we do this at scale,\u201d Winrow said. \u201cYou need a certain differentiation period for the iPSCs to form into the neurons that you want to study. There\u2019s also a certain QC [quality control] that you need to do to make sure that those neurons are what we expect them to be, and that that\u2019s robust and reproducible.\u201d<\/p>\n

Recursion subjected the potential targets they identified to what the company said was a rigorous validation process developed jointly with Genentech. Candidate targets advanced through successive stages of pathway validation, functional validation, and disease validation to determine whether modulating the target altered neurological disease phenotype. Only targets that consistently showed compelling evidence across<\/p>\n

each stage advanced into a validation package.<\/p>\n

Researchers from Recursion and Genentech applied a large-scale perturbation set using whole-genome CRISPR-Cas9 knockouts spanning more than 17,000 genes and thousands of small molecules. \u201cYou look for what we would call gene-compound interactions, to uncover some of those insights, at the same time as looking at the gene-gene interactions,\u201d Winrow said.<\/p>\n

\u201cWe\u2019re looking at whole genome-wide knockout, not just a handful of areas or pathways of interest. That\u2019s really a big game changer, in that we have this broad view,\u201d he added. \u201cAs we perturb the cells, we start to see the known actors. But more importantly, we\u2019re starting to see these unexplored areas really come to light. So that\u2019s what\u2019s changed, taking that broad view at a genome-wide level with the scale and throughput that we have at Recursion.\u201d<\/p>\n

46M+ images<\/p>\n

With the cells produced and perturbations added in, the next step entails imaging designed to capture more than 46 million cellular images. Each image is analyzed across hundreds of features such as mitochondrial shape, nuclear morphology, using AI foundational models.<\/p>\n

\u201cWhat even is more mind-blowing beyond that is there are multiple features within each of those images,\u201d Winrow said. \u201cTraditionally as a scientist, I\u2019d go in and I\u2019m really interested in mitochondria. So, I look at the image and I say \u2018Wow, am I seeing mitochondrial fragmentation?\u2019 Well, that\u2019s great. Yes, I am, right?\u2019 But if you\u2019re looking at hundreds and hundreds of different features, that could be a mitochondrial shape, it could be nuclear capacity, it could be a whole bunch of different things that the AI models are trained upon, that then enables a real richness to come out of that dataset.\u201d<\/p>\n

\u201cSo, it\u2019s not just the scale of those images, it\u2019s actually what\u2019s within those images that we require the AI approaches to really uncover,\u201d Winrow added.<\/p>\n

The resulting data is analyzed to identify patterns resembling disease biology using Recursion\u2019s BioHive-2 supercomputer<\/a>, completed in 2024 based on Nvidia technology and proprietary AI models. Those insights are then turned into hypotheses that govern further research and ultimately, validated targets.<\/p>\n

\u201cEach target is individual. They are related to a core disease process,\u201d Winrow said. \u201cWe have these core areas of biology that are looked at by a lot of different groups. We want to understand the unexplored biology around those areas, and that can be anything. It\u2019s an unbiased approach, so all of those things that are associated have not necessarily been connected to this target in the past, so you come up with all sorts of different targets.<\/p>\n

\u201cValidation, then, is central to that core biology in exploring a whole bunch of different new intersecting targets,\u201d he added.<\/p>\n

Next steps<\/p>\n

Next steps for the partners include advancing the discovery program from a target into a drug, using Recursion\u2019s chemistry platform to design a potential first-in-class molecule\u2014as well as identifying and validating additional targets for potential new programs.<\/p>\n

Recursion said it will continue to combine its phenomics dataset with Genentech\u2019s proprietary transcriptomics data to build additional multimodal maps designed to explore potential novel targets and pathways by systematically linking gene perturbations to cellular phenotypes.<\/p>\n

The neuronal map is one of two whole genome neuroscience phenomaps produced by the Recursion-Roche-Genentech partnership. The other is a map of specialized microglial immune cells unveiled last year<\/a>, which the companies also plan to use toward revealing significant new targets in neurodegenerative diseases.<\/p>\n

\u201cThis provides us really two distinct but CNS-focused maps that are rooted in human biology. I think the opportunities are there to really mine both of those. The neuro map is a little bit ahead, and so we\u2019ve been able to take some of the learnings that we gained there and apply that to our work on the microglia side as well.\u201d<\/p>\n

The two neuro-focused maps, in turn, are among six total whole genome phenomaps produced by the companies; the other four are designed to discover targets for a single undisclosed indication in GI oncology. The maps are designed to allow Recursion, Roche, and Genentech to explore potential undiscovered targets and pathways, systematically linking gene perturbations to cellular phenotypes.<\/p>\n

\u201cBecause we can reuse these maps again and again, I might find something in the microglia map that\u2019s really intriguing that I can now follow up in in the neuron map, and vice versa,\u201d Winrow commented. \u201cI think that\u2019s a real power of this approach as well.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"Christopher Winrow, PhD, Recursion\u2019s vice president of neuroscience, inside the company\u2019s lab. Recursion marked a milestone in its…\n","protected":false},"author":2,"featured_media":130131,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[24,25,51828,1941,27670,65168,65166,9965,65167,66,65169,65170,29094],"class_list":["post-130130","post","type-post","status-publish","format-standard","has-post-thumbnail","category-ai","tag-ai","tag-artificial-intelligence","tag-crispr","tag-drug-discovery","tag-gen-edge","tag-genentech","tag-induced-pluripotent-stem-cells","tag-industry-news","tag-nervous-system-diseases","tag-news","tag-recursion-pharmaceuticals","tag-roche-company","tag-transcriptomics"],"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts\/130130","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/comments?post=130130"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts\/130130\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/media\/130131"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/media?parent=130130"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/categories?post=130130"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/tags?post=130130"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}